Pfizer · 10 hours ago
Senior Manager Finance, Abrysvo OA
Pfizer is seeking a dynamic and skilled Senior Manager to join their Biopharma Finance team, supporting Abrysvo OA as well as additional pan-Vaccines initiatives. The successful candidate will be responsible for comprehensive financial management, including budgeting, forecasting, and reporting, while acting as a key commercial business partner within a highly matrix environment.
BiotechnologyHealth CareMedicalPharmaceuticalPrecision Medicine
Responsibilities
Provide strategic business finance support to the Brand Marketing Team for Abrysvo Older Adult indication
Provide financial partnership on business initiatives that unlock business value across assigned US commercial teams, ensuring compliance with laws and company policies
Establish effective working relationships with business partners, offering financial leadership, business consultation, and analytical support to the commercial teams
Generate performance reports for the brand, including weekly and monthly trackers for the brand lead and other stakeholders
Analyze brand GTN. Evaluate contracting performance from a volume and price perspective with their corresponding impact on brand P&L. Assess and model MS and GTN forecast by top customers for retail and non-retail channels
Partner with MMF to assess Medicare Part D rebates estimate
Lead the Older Adults vs Maternal financial revenues allocation process
Create, maintain, and update the Vaccines sales models for Operating Plan, LE forecasts and other specific scenarios according to latest market developments and trends
Submission of all FP&A, Controllers and US finance deliverables for Abrysvo, such as Local Mosaic submissions, monthly VEP validations, royalties, external reporting web-forms, etc
Analyze and provide insights into brand P&L performance including revenues, cost of sales, and A&P spend. Complete monthly and quarterly US alliance processes and reconciliations
Actively participate in Primary Care team activities such as simplification/automation initiatives, and US Commercial Finance workstreams
Support US Vaccines Finance team with other cross-portfolio activities (e.g. contracting forecasting, etc)
Qualification
Required
6+ years of finance experience; 5+ years with an advanced degree
Experience in Product P&L financial management and corresponding business knowledge
Expertise in financial modeling & analysis, budgeting, and forecasting
Strong negotiation and influencing skills
Solid understanding of Generally Accepted Accounting Principles and Pfizer's financial systems
Excellent analytical, interpersonal, and communication skills (oral, written & presentations) with the ability to effectively summarize critical information into clear, concise, and insightful updates for senior leadership
Ability to synthesize multiple data sources to provide perspective
Proficiency in performing complex data analysis and working in a matrix environment
Candidate demonstrates a breadth of diverse leadership experiences and capabilities including: the ability to influence and collaborate with peers, develop and coach others, oversee and guide the work of other colleagues to achieve meaningful outcomes and create business impact
Preferred
Advanced degree, preferably finance, an MBA/CPA
Experience with Gross to Net components such as Chargebacks, Rebates, CoPay
Life Sciences Industry experience
Benefits
Participation in Pfizer’s Global Performance Plan with a bonus target of 17.5% of the base salary
Eligibility to participate in our share based long term incentive program
401(k) plan with Pfizer Matching Contributions
Additional Pfizer Retirement Savings Contribution
Paid vacation
Holiday and personal days
Paid caregiver/parental and medical leave
Health benefits to include medical, prescription drug, dental and vision coverage
Company
Pfizer
Pfizer is a biopharmaceutical company that discovers, develops, and delivers medicines and vaccines.
Funding
Current Stage
Public CompanyTotal Funding
$38BKey Investors
Starboard Value
2025-11-21Post Ipo Debt· $6B
2024-10-07Post Ipo Equity· $1B
2023-05-16Post Ipo Debt· $31B
Recent News
2026-01-14
Longevity.Technology
2026-01-14
Pharma Letter
2026-01-14
Company data provided by crunchbase